Mozavaptan
Chemical compound
- none
- In general: ℞ (Prescription only)
- N-[4-(5-Dimethylamino-2,3,4,5-tetrahydro-1-benzazepine-1-carbonyl)phenyl]-2-methylbenzamide
- 137975-06-5 Y
- 119369
- 2197
- 106618 Y
- 17OJ42922Y
- ChEMBL420762 Y
- DTXSID8057641
- Interactive image
- Cc1ccccc1C(=O)Nc2ccc(cc2)C(=O)N3c4ccccc4C(CCC3)N(C)C
InChI
- InChI=1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31) Y
- Key:WRNXUQJJCIZICJ-UHFFFAOYSA-N Y
Mozavaptan (INN) is a vasopressin receptor antagonist marketed by Otsuka. In Japan, it was approved in October 2006 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH) due to ADH producing tumors.
References
- Spreitzer H (November 20, 2006). "Neue Wirkstoffe - Conivaptan". Österreichische Apothekerzeitung (in German) (24/2006).
- "Conivaptan hydrochloride". Molecule of the Month. Prous Science. November 2006. Archived from the original on 2012-02-13.
- v
- t
- e
(and etacrynic acid)
CA inhibitors (at PT) | |
---|---|
Loop (Na-K-Cl at AL) | |
Thiazides (Na-Cl at DCT, Calcium-sparing) | |
Thiazide-likes (primarily DCT) |
ESC blockers | |
---|---|
Aldosterone antagonists |
(DCT and CD)
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e